Back Hepatitis B Hepatitis B Topics HBV Treatment

Coverage of Digestive Disease Week 2013 coverage of the 2013 Digestive Disease Week annual meeting (DDW 2013) in Orlando, Florida, May 18-21, 2013.

Conference highlights include direct-acting hepatitis C drugs, new strategies for using approved HCV protease inhibitors and interferon/ribavirin, and interferon-free regimens.

Full listing by topic DDW 2013 conference section



EASL 2013: Do Asian Patients Respond Better to Pegylated Interferon for Hepatitis B?

Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at the EASL International Liver Congress(EASL 2013) last month in Amsterdam. The study also showed that early hepatitis B surface antigen (HBsAg) decline is a predictor of treatment response in some patients.


Read more:

Coverage of the 2013 EASL International Liver Congress coverage of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) in Amsterdam, April 24-28, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, and prevention and treatment of hepatocellular carcinoma.

Full listing by topic

EASL 2013 conference section



EASL 2013: Truvada Works Best for Immune-Tolerant Hepatitis B Patients -- But Do They Need Treatment?

A combination of tenofovir and emtricitabine (the drugs in Truvada) suppressed hepatitis B virus (HBV) replication more than tenofovir alone over 4 years for people with inactive or immune-tolerant disease, researchers reported at the EASL International Liver Congress (EASL 2013) this week in Amsterdam. The benefits of treatment at this early stage, however, remain uncertain.


Read more:

EASL 2013: Long-term Tenofovir Reduces Liver Cancer Risk in People with Chronic Hepatitis B

Long-term treatment with tenofovir (Viread) lowered the risk of developing hepatocellular carcinoma among people with chronic hepatitis B, with a notable divergence from expected rates after about 5 years, according to a report presented at the at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.


Read more: